ArticleTheranostics2020
A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor.Journal of pharmaceutical analysis · 2025Article
- Ultrashort Peptides as Stabilizing Agents for Colloidal Nanogold.ACS applied materials & interfaces · 2025Article
- Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity.Journal of nanobiotechnology · 2025Article
- Bringing p53 Back: A Prion-Powered Attack on Retinoblastoma.International journal of biological sciences · 2025Article
- Selenium nanoparticle-delivered MDM2 inhibitor reactivates p53 and reprograms tumor immune microenvironment in colorectal cancer.Frontiers in immunology · 2025Article
- A bifunctional peptide-selenium nanocomposite for lysosomal degradation of PD-L1 and enhanced cancer immunotherapy.Frontiers in immunology · 2025Article
- Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer.Frontiers in immunology · 2025Article
- Bionic Power Play: Dual-Targeting MDMX/MDM2 to Reboot p53 to Beat Lung Adenocarcinoma's Immune Tricks.International journal of nanomedicine · 2025Article
- Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?Molecular biology reports · 2024Review
- Reinvigoration of cytotoxic T lymphocytes in microsatellite instability-high colon adenocarcinoma through lysosomal degradation of PD-L1.Nature communications · 2024Article
- A Transdermal Prion-Bionics Supermolecule as a RAB3A Antagonist for Enhancing Facial Youthfulness.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Visualizing the global trends of peptides in wound healing through an in-depth bibliometric analysis.International wound journal · 2024Article
- Article
- Cocktail hepatocarcinoma therapy by a super-assembled nano-pill targeting XPO1 and ATR synergistically.Journal of pharmaceutical analysis · 2023Article
- Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2.Journal of advanced research · 2023Article
- Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.Theranostics · 2023Article
- A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy.Frontiers in immunology · 2023Article
- An innovative gene expression modulating strategy by converting nucleic acids into HNC therapeutics using carrier-free nanoparticles.Frontiers in immunology · 2023Article
- Review
- A manganese (II)-based coordinative dendrimer with robust efficiency in intracellular peptide delivery.Bioactive materials · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide-derived nanocomposites have been exhibiting fascinating biological advantages, including but not limited to excellent biocompatibility, biological degradation, high targetability and subsequent potent therapeutic efficacy. While some successes have been achieved in the nanoengineering of peptide-based architectures with defined dimensions and medical functions, enormous challenges remain about clinical nano-pharmaceutics of peptides, especially those modulating intracellular protein-protein interactions (PPIs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.